A photograph of a man and a woman smiling while looking at a doctor who is holding a folder. The doctor is wearing a white lab coat and a stethoscope.

Bryn Mawr Hospital Cancer Program

Annual Report based
on 2009 Statistics



Bryn Mawr Hospital
Main Line Health

Message from the Chairman of the Cancer Committee

Bryn Mawr Hospital provided diagnosis and/or treatment to 1,284 cancer patients in 2009. This is a 3% decrease versus 2008. Breast cancer accounts for the largest number of cancer patients at Bryn Mawr, with 328 women diagnosed and treated at our Center compared to 299 in 2008. Additionally, 224 men were diagnosed and treated here for prostate cancer. Our breast cancer program is among the largest in the metropolitan area. The Bryn Mawr cancer program has received a full three-year accreditation from the American College of Surgeons with six commendations, including for prevention and early detection programs, patient care improvements and clinical research participation.

The Cancer Center includes a state-of-the-art Comprehensive Breast Center with breast diagnostic services including digital mammography, breast ultrasound and MRI. Biopsy options include stereotactic, ultrasound and MRI. The team is led by breast surgeon and Program Director Thomas Frazier, MD, and John Stassi, MD, Director of Breast Imaging. Key elements in making ours one of the most comprehensive breast centers in the area include dedicated breast imagers, nurse coordinators, a high risk genetic (breast and colorectal cancer) assessment program, a weekly multidisciplinary breast conference reviewing every breast cancer case, and patient education, all in a beautiful facility. Additionally, the Center now has an accredited fellowship in breast cancer surgery, training two Fellows each year to be breast surgeons. The Breast Center received a three-year National Accreditation Program for Breast Centers (NAPBC) Accreditation in March 2009, becoming one of the first Accredited Centers in Southeastern Pennsylvania.

The Cancer Center is comprised of an inpatient unit, operating suites for specialized cancer surgery (including laparoscopic and thoracoscopic) and new state-of-the-art facilities for radiation therapy, including High Dose Rate brachytherapy, 3-D conformal radiotherapy, IMRT, IGRT,

stereotactic radiation, partial breast radiation, and the new Trilogy System at the Newtown Square Campus. Also provided are areas for outpatient chemotherapy administration, complete diagnostic and therapeutic radiology services (including chemoembolization and PET/CT), fertility counseling for chemotherapy recipients and genetic counseling for hereditary cancer risk. A team of more than 40 physician specialists, oncology nurses, technicians, researchers, nutritionists, geneticists, and psychosocial counselors provide care for our patients.

The primary focus in 2009 continued to be clinical cancer research. Bryn Mawr Hospital, along with Lankenau and Paoli Hospitals, is part of Main Line Health's third National Cancer Institute Community Clinical Oncology Program (CCOP) research grant. Bryn Mawr Hospital's Cancer Program continued its participation with the National Cancer Institute's major cooperative research groups, including the Eastern Cooperative Oncology Group (ECOG), National Surgical Breast and Bowel Project (NSABP), Radiation Therapy Oncology Group (RTOG), and Gynecology Oncology Group (GOG). In 2009 we experienced a very successful research year with 72 patients enrolling in one of the CCOP research protocols.

The Bryn Mawr Hospital Cancer Program, through its facilities and available resources, is able to provide virtually every cancer care and support service to cancer patients and their families along Philadelphia's Main Line.



Steven C. Cohen, MD
Chief, Hematology-Oncology
Chair, Cancer Committee

Bryn Mawr Cancer Clinical Trials Program

Cancer clinical trials evaluate new approaches to cancer treatment and prevention by providing patients at all stages of cancer with cutting edge strategies. This may involve surgery, chemotherapy, radiation therapy, biologic therapy, or a combination of these modalities. Since 1994, the cancer program at Bryn Mawr has been providing access to National Cancer Clinical Trials as a component of the Main Line Health CCOP: Cancer Clinical Trials Program. A CCOP is a National Cancer Institute (NCI) sponsored Cancer Clinical Trials Program. Our Main Line Health CCOP program is one of only 50 in the nation. 2009 marks the 16th year of our NCI grant, which gives our patients access to nationally recognized cancer clinical trials right where they live. Our CCOP program is affiliated with the following research bases: Eastern Cooperative Oncology Group (ECOG); Gynecologic Oncology Group (GOG); MD Anderson Cancer Center; National Surgical Adjuvant Breast and Bowel Project (NSABP); Radiation Therapy Oncology Group (RTOG), and Wake Forest Comprehensive Cancer Center.

Bryn Mawr Hospital Cancer Program also participates in pharmaceutical sponsored clinical trials, and investigator initiated research. Bryn Mawr clinicians are involved in innovative research collaborations with the basic scientists of the Lankenau Institute for Medical Research (LIMR). This is the premiere of how basic science discovery is translated into patient care.

More than 85% of cancer patients are diagnosed and treated in their local communities. We are empowering our community by providing access to state of the art therapy in our fight against cancer.

Maria Hendricks, MSN, RN, CCRP
Administrator, Main Line Health CCOP:
Cancer Clinical Trials Program

Report on Breast Cancer | 2009

Breast cancer continues to be a main focus of the oncology program at Bryn Mawr Hospital and particularly the Bryn Mawr Hospital Comprehensive Breast Center. All diagnostic tools are employed and radiation oncology and medical oncology programs are individualized for each patient, based on improved knowledge regarding the prognostic implications of receptors, HER-2 analysis and, when indicated, Oncotype DX assay.

From 2004 through 2009, there was a 58.8% increase in needle localization biopsies carried out at BMH. In 2009, 130 MRI-guided breast biopsies were also performed. The high risk program has now enrolled 250 patients, with 145 receiving OncoVue testing with infrared imaging. Surgical volume also continues to increase yearly. The breast center continues to offer a program which includes genetic counseling and testing. Also offered are multi-disciplinary conferences, breast surgery fellowships and intra- and inter-hospital conferences, including Breast Health Partnership and Breast Health Consortium.

The surgical program continues to offer a range of approaches from segmental resection/sentinel node mapping to bilateral mastectomy. Patients are also offered either immediate reconstruction or, in patients to be treated with adjuvant radiotherapy, insertion of an expander with reconstruction to follow radiotherapy.

The Radiation Oncology Department employs up-to-date techniques on the linear accelerator to ensure homogeneous radiotherapy to the breast, which includes breath-holding and respiratory gating techniques along with IGRT/IMRT, to deliver treatment to the breast, with minimal dosage to lung and/or heart. Our program also offers, for select early-stage patients, a partial breast approach employing high-dose brachytherapy with Ir-192 or 3D conformal external beam therapy to deliver treatment twice daily over five treatment days. Over 500 patients have been treated with this program to date.


Medical oncology also offers the latest in treatment tailored to the individual, employing pathology, receptors, HER-2 gene analysis and Oncotype DX assay where appropriate, as well as referring patients for genetic counseling and testing for BRCA1/BRCA2 mutations.

At BMH in 2009, there were 328 analytic breast patients, of whom 76 were Stage 0; 152 Stage I; 70 Stage II; 25 Stage III; 4 Stage IV and

1 Unknown Stage. Breast cancer patients treated from 2000-2004 have survival rates of 96% Stage 0; 94% Stage I; 84% Stage II; 57% Stage III and 10% Stage IV; compared to national benchmark of 95.1% Stage 0; 91.2% Stage I; 82.7% Stage II; 58.3% Stage III and 19.5% Stage IV¹. In 2009, as indicated in the pie chart, 20% were treated with

First Course Treatment Breast 2009

n=328



surgery alone; 59% had radiation as part of their overall management; 26% had chemotherapy; and 52% had hormonal therapy.

The Bryn Mawr Hospital Oncology Program remains committed to the finest breast cancer care, including all appropriate ancillary services, such as survivorship events and activities, breast nurse navigators and several groups for support and education, with the goal of producing the best results with the least physical and emotional discomfort for our patients.

Richard J. Carella, MD
Radiation Oncologist
Bryn Mawr Hospital

Oncology Data Services

The Oncology Data Services Department at Bryn Mawr Hospital manages and analyzes clinical data on patients and is the first line in providing data for national statistics, research, quality improvement, cancer prevention and surveillance.

As required by law, cancer incidence is reported to the Pennsylvania Cancer Registry of the Department of Health and to the National Cancer Database for comparative analysis with similar facilities and national organizations. Data is also sent to the Facility Information and Profile System of the Commission on Cancer (CoC) for use in tracking trends in cancer research.

In 2009, 1,284 new cancer cases were accessioned by BMH. Among these cases, 1,145 were analytic (diagnosed and treated here) and 139 were non-analytic (diagnosed and/or treated elsewhere and receiving subsequent treatment here). Our most frequent sites for 2009 were breast, prostate, lung/bronchus, colon/rectum and melanoma. With a reference date of 2001, we provide lifetime

follow-up for approximately 6,000 patients. Lifetime follow-up is required for approval from the Commission on Cancer and also to ensure continuity of patient care.

In June 2010, BMH was surveyed by the Commission on Cancer and received full three-year accreditation with six commendations.

As the incidence of cancer increases, the knowledge and skills necessary to manage data become more complex. We are currently staffed with three Oncology Data Specialists who keep abreast of the latest innovations and advancements in the oncology field by attending annual state, local, and/or national educational programs.

Commitment and dedication are the catalysts that continue to motivate and inspire us to rise to the challenges of our profession and make us proud to be part of a comprehensive oncology care team.


Karen Dysleski, RHIA, CTR

Esther Kert, RHIA, CTR

Jane Palumbo, CTR

Kaplan-Meier Observed Survival by Best AJCC Stage

Female Breast 2000-2004



Site Distribution Report—AJCC Staging for Bryn Mawr Hospital

Study Group: 2009 Analytic Cases (newly diagnosed)		AJCC Stage										
Primary Site	Cases	0	1	2	3	4	88	Unk	Male	Female	% BMH Database	ACS Est. Figures*
Bladder	73	48	12	6	3	3	0	1	54	19		
Brain/CNS	35	0	0	0	0	0	35	0	15	20		
Breast	328	76	152	70	25	4	0	1	1	327	29%	13%
Colon/Rectum	80	1	23	22	19	14	1	0	48	32	7%	10%
Esophagus	4	0	0	1	0	3	0	0	4	0		
Kidney	35	1	25	3	4	2	0	0	23	12		
Larynx	6	2	2	0	1	1	0	0	6	0		
Leukemia	5	0	0	0	0	0	5	0	4	1		
Lip and Oral Cavity	13	1	4	0	2	5	0	1	6	7		
Lung	110	0	18	4	29	55	4	0	52	58	10%	15%
Lymphoma	33	0	7	7	7	10	1	1	18	15		
Melanoma	74	32	23	7	0	4	0	8	40	34	7%	5%
Myeloma	4	0	0	0	0	0	4	0	2	2		
Other	34	0	4	9	4	6	9	2	11	23		
Ovary	8	0	0	0	2	6	0	0	0	8		
Pancreas	15	0	2	4	3	6	0	0	5	10		
Prostate	224	0	0	198	23	3	0	0	224	0	20%	13%
Stomach	9	0	2	1	2	4	0	0	5	4		
Testis	10	0	8	1	1	0	0	0	10	0		
Thyroid	23	0	19	2	1	0	0	1	8	15		
Unknown Primary	9	0	0	0	0	0	9	0	4	5		
Uterus	13	0	9	0	3	0	0	1	0	13		
Total	1,145	161	310	335	129	126	68	16	540	605	71%	56%

The most frequent cancer sites for 2009 are highlighted in the above table and represent the percentage of cancer incidence seen at Bryn Mawr Hospital as comparable to the American Cancer Society's national estimates. They are in descending order: Breast, Prostate, Lung, Colon/Rectum, and Melanoma.

In addition, 139 cases were diagnosed and treated elsewhere and received subsequent treatment at Bryn Mawr Hospital for a total of 1,284 cases in 2009.

*Cancer Facts & Figures 2009, American Cancer Society

Bryn Mawr Hospital Cancer Committee—2009/2010

Steven C. Cohen, MD	Chairman, Medical Oncology	Brenda DeFeo, MBA	Administration
Thomas Frazier, MD	ACoS Liaison, Breast Surgery	Deborah Dickerson, RHIT, CTR	Oncology Data Services
Erik Assarsson, MD	Radiation Oncology	Karen Dysleski, RHIA, CTR	Oncology Data Services
Marchello Barbarisi, MD	Radiology	Mary Beth Flynn, RN, BSN, MA, OCN	Radiation Oncology
Leigh Bergmann, MD	Urology	Maria Hendricks, MSN, RN, CCRP	MLH CCOP: Cancer Clinical Trials Program
Andrea Barrio, MD	Breast Surgery	Esther Kert, RHIA, CTR	Oncology Data Services
Richard Carella, MD	Radiation Oncology	John McClelland	Community Liaison
Tracy d'Entremont, MD	Medical Oncology	Kathleen McDevitt, APRN, AOCN, MSN, BC-PC	Palliative Care/Pain Management
John Devlin, MD	Medical Oncology	Stephanie Moore, DPT	Physical Medicine & Rehabilitation
James Paulson, MD	Pathology	Eileen Morgans, RN, BSN, CBCN	Comprehensive Breast Center
Philip Pearson, MD	Colorectal Surgery	Melissa Naegle, Pharm. D.	Pharmacy
Sandra Schnall, MD	Medical Oncology	Jane Palumbo, CTR	Oncology Data Services
Michael Walker, MD	Thoracic Surgery	Lynne Quinn, RN, MSN, CRNP, AOCNP	Radiation Oncology
Joan Zeidman, MD	Gynecology	Catherine Sargent, MS, RN, BC, AOCNS	Oncology Nursing
Margie Arnone, MS, RD	Nutrition	Priscilla Smartt	Womens' Board
Beth Bell, MSW	Social Work	Ruthmary Strohm, MSW	Social Work
Marisa Benjamin	Development/Marketing	Laura Tansey, RN	Quality Improvement
Tracey Blickos, RN	Community Services	Suzanne Tucci, RN, BSN, OCN	Oncology Nursing
Kelly Bradford	American Cancer Society	Rosemary Wiggins, RN, BSN, OCN, CCRP	MLH CCOP: Cancer Clinical Trials Program
		Gail Wright, MS	Community Services

Bryn Mawr Hospital Cancer Service Directory

Breast Prosthesis Program

[1.800.227.2345](#)

Free breast prosthesis program co-sponsored by the American Cancer Society.

Cancer Risk Assessment and Genetic Testing Programs

[484.337.8767](#)

Offers genetic assessment, counseling and testing for high risk individuals.

Clinical Trials and Cancer Prevention Research

[484.337.3686](#)

Provides patients access to NCI-sponsored clinical research and prevention trials.

Community Education and Screening

[484.337.8720](#)

Provides educational programs and cancer screenings to the community.

"Look Good, Feel Better"

[1.866.225.5654](#)

American Cancer Society sponsored program, providing cosmetic instruction for women during and after cancer treatment.

Lymphedema Management Program

[484.337.3360](#)

Provides early and continuing treatment for patients with Lymphedema.

Nutritional Services

[484.337.3207](#)

Registered Dietician counsels individuals and support groups during cancer care.

Oncology Data Services

[484.337.3727](#)

Comprehensive data management system for the collection of malignant or neoplastic disease. Registrars provide monitoring, analysis and lifetime follow-up of patients diagnosed with cancer.

Physical Medicine and Rehabilitation

[484.337.3360](#)

Advice and instruction concerning exercises and/or ambulation for patients undergoing treatment.

Radiation Oncology

[484.337.8510](#)

Advanced, comprehensive, state-of-the-art radiation treatment of cancer in a community setting.

Social Work

[484.337.3594](#)

Social workers provide psychosocial support and counseling for patients and their families.

Support Groups

[484.337.3594](#)

Information, education and support to patients recovering from cancer.

Wig Program

[484.337.8724](#)

Free wig program for women who are anticipating or experiencing a change in their physical appearance.

Women's Health Source

[1.866.225.5654](#)

A free membership club offering information on a wide variety of health issues important to women.

130 South Bryn Mawr Avenue
Bryn Mawr, PA 19010

1.866.CALL.MLH
mainlinehealth.org



Bryn Mawr Hospital
Main Line Health

Well ahead.SM